Skip to main content

Market Overview

UPDATE: Barclays Capital Initiates Coverage On Medivation On Multiple Upside Drivers


In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Medivation Inc (NASDAQ: MDVN) with an Overweight rating and $130.00 price target.

In the report, Barclays Capital noted, “Medivation's Xtandi is now set to have broader reach in prostate cancer with a pre-chemo label and a focus on the much larger urologist prescriber base. As a result, we're ~10% ahead of consensus on total revenues in 2015. In addition, phase 2 data in 1H15 in two trials (STRIVE, TERRAIN) should further differentiate Xtandi from JNJ's Zytiga and could drive off-label use earlier in the prostate cancer paradigm. With beatable expectations for Xtandi in the US/EU/JPN and expansion ahead in prostate/breast cancer, we think that Medivation's momentum last year will persist in 2015. We're initiating coverage with an Overweight rating and $130 target.”

Medivation closed on Monday at $100.02.

Latest Ratings for MDVN

Sep 2016SunTrust Robinson HumphreyTerminatesNeutral
Aug 2016BMO CapitalMaintainsMarket Perform
Aug 2016CitigroupDowngradesBuyHold

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings


Related Articles (MDVN)

View Comments and Join the Discussion!

Posted-In: Barclays Capital Geoffrey MeachamAnalyst Color Initiation Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at